Abstract
Substantial evidence indicates that neuroactive kynurenine metabolites play a role in the normal physiology of the human brain, and are involved in the pathology of neurodegenerative disorders such as Parkinsons disease and Huntingtons disease. A side-arm product of the pathway, kynurenic acid (KYNA), which is synthesized by the irreversible transamination of kynurenine (KYN) by kynurenine aminotransferases (KAT I and KAT II), is an excitatory amino acid receptor antagonist. In the present study, we measured the level of KYNA and the activities of the biosynthetic enzyme isoforms KAT I and KAT II in the plasma and in the erythrocytes (RBCs) of patients with cervical dystonia or blepharospasm and in age-matched controls. The KAT I and KAT II activities were significantly lower in the plasma of the patients in both subgroups. In the RBCs, only the KAT I activity was elevated significantly. The KYNA concentration was unchanged in both type of patients. These data support the contribution of an altered kynurenine metabolism to the pathogenesis of focal dystonia.
Keywords: Cervical dystonia, blepharospasm, kynurenine aminotransferase, kynurenic acid, excitotoxicity
Medicinal Chemistry
Title: Peripheral Kynurenine Metabolism in Focal Dystonia
Volume: 3 Issue: 3
Author(s): Zsuzsanna Hartai, Peter Klivenyi, Tamas Janaky, Botond Penke, Laszlo Dux and Laszlo Vecsei
Affiliation:
Keywords: Cervical dystonia, blepharospasm, kynurenine aminotransferase, kynurenic acid, excitotoxicity
Abstract: Substantial evidence indicates that neuroactive kynurenine metabolites play a role in the normal physiology of the human brain, and are involved in the pathology of neurodegenerative disorders such as Parkinsons disease and Huntingtons disease. A side-arm product of the pathway, kynurenic acid (KYNA), which is synthesized by the irreversible transamination of kynurenine (KYN) by kynurenine aminotransferases (KAT I and KAT II), is an excitatory amino acid receptor antagonist. In the present study, we measured the level of KYNA and the activities of the biosynthetic enzyme isoforms KAT I and KAT II in the plasma and in the erythrocytes (RBCs) of patients with cervical dystonia or blepharospasm and in age-matched controls. The KAT I and KAT II activities were significantly lower in the plasma of the patients in both subgroups. In the RBCs, only the KAT I activity was elevated significantly. The KYNA concentration was unchanged in both type of patients. These data support the contribution of an altered kynurenine metabolism to the pathogenesis of focal dystonia.
Export Options
About this article
Cite this article as:
Hartai Zsuzsanna, Klivenyi Peter, Janaky Tamas, Penke Botond, Dux Laszlo and Vecsei Laszlo, Peripheral Kynurenine Metabolism in Focal Dystonia, Medicinal Chemistry 2007; 3 (3) . https://dx.doi.org/10.2174/157340607780620707
DOI https://dx.doi.org/10.2174/157340607780620707 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Enhanced Hyperthermia Induced by MDMA in Parkin Knockout Mice
Current Neuropharmacology Galectin-1 as a Potential Therapeutic Agent for Amyotrophic Lateral Sclerosis
Current Drug Targets Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Area, Age and Gender Dependence of the Nucleoside System in the Brain: a Review of Current Literature
Current Topics in Medicinal Chemistry Optimization and Assay of Antioxidant Potential of Two Penicillium spp. by Different Procedures
Current Biotechnology A Novel Approach for Substitution of Sulfonate Group by (1H)-imidazole moiety: An Application for Synthesis of Novel Benzyl Imidazolyl carbamates
Letters in Organic Chemistry A Comparative Study Among Various Statistical Tests Using Microarray Gene Expression Data
Current Bioinformatics The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments
Current Drug Targets Phosphate-Affinity Gel Electrophoresis Using a Phos-Tag Molecule for Phosphoproteome Study
Current Proteomics Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design